Highlights Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-15 pm EST			5-day change	1st Jan Change
105.24 ^USD	-0.67%		-0.64%	+6.55%

Jan. 15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Jan. 13	TD Cowen Adjusts Price Target on Incyte to $128 From $101, Maintains Buy Rating	MT

Highlights

Jan. 05	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as First-Line Treatment for Diffuse Large B-Cell Lymphoma	CI
Jan. 05	Incyte announces positive topline results from study of tafasitamab	RE
Dec. 22	Incyte Says Its Cancer Drug Has Received Approval in Japan for Follicular Lymphoma	MT
Dec. 17	Incyte announces European Commission approval of Minjuvi (tafasitamab)	RE
Dec. 17	Incyte Announces European Commission Approval of Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
Dec. 17	Incyte Says European Commission Approves Minjuvi Combination Therapy for Follicular Lymphoma	MT
Dec. 08	Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation	MT
Dec. 07	Incyte Announces New Positive Data for INCA033989, Its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented At ASH 2025	CI
Dec. 07	Incyte's First-In-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA	CI
Dec. 06	Prelude Therapeutics Incorporated Presents Data at the 2025 ASH Annual Meeting from Its Myeloproliferative Neoplasm Programs	CI
Nov. 17	Incyte Announces Positive CHMP Opinion for Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
Nov. 17	Incyte's Minjuvi Gets EU Committee Recommendation as Potential Treatment for Follicular Lymphoma	MT
Nov. 12	Prelude Therapeutics Q3 net loss narrows	RE
Nov. 07	Incyte Insider Sold Shares Worth $534,813, According to a Recent SEC Filing	MT
Nov. 05	Incyte Insider Sold Shares Worth $289,017, According to a Recent SEC Filing	MT
Nov. 03	Incyte Corporation Announces More Than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting	CI
25-10-28	Incyte lifts forecast for key drug Jakafi, but pipeline rejig drags shares	RE
25-10-28	Incyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-28	Incyte boosts annual sales forecast of blood cancer drug after strong quarter	RE
25-10-28	Incyte Corporation Revises Earnings Guidance for the Fiscal Year 2025	CI
25-10-28	Incyte Q3 Non-GAAP Earnings, Revenue Increase	MT
25-10-28	Earnings Flash (INCY) Incyte Corporation Reports Q3 Revenue $1.37B, vs. FactSet Est of $1.25B	MT
25-10-28	Earnings Flash (INCY) Incyte Corporation Posts Q3 Adjusted EPS $2.26 per Share, vs. FactSet Est of $1.58	MT
25-10-28	Drugmaker Incyte tops Q3 revenue estimates, raises guidance	RE
25-10-25	Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Incyte Corporation

Equities

INCY

US45337C1027

Pharmaceuticals

Highlights

Filters